Pityriasis rosea–like rash after messenger RNA COVID-19 vaccination: A case report and review of the literatureCapsule Summary
A spectrum of cutaneous reactions to SARs-CoV-2 (COVID-19) vaccines have been reported in the literature. We present a case of a pityriasis rosea-like rash occurring after Pfizer COVID-19 vaccination and review cases of pityriasis rosea (PR)/PR-like eruption (PR-LE) after mRNA COVID-19 vaccine publi...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-06-01
|
| Series: | JAAD International |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666328722000141 |
| _version_ | 1811257452031639552 |
|---|---|
| author | Jordan E. Buckley, MD Laura N. Landis, BA Ronald P. Rapini, MD |
| author_facet | Jordan E. Buckley, MD Laura N. Landis, BA Ronald P. Rapini, MD |
| author_sort | Jordan E. Buckley, MD |
| collection | DOAJ |
| description | A spectrum of cutaneous reactions to SARs-CoV-2 (COVID-19) vaccines have been reported in the literature. We present a case of a pityriasis rosea-like rash occurring after Pfizer COVID-19 vaccination and review cases of pityriasis rosea (PR)/PR-like eruption (PR-LE) after mRNA COVID-19 vaccine published in the medical literature. Of the 30 cases found, none experienced severe adverse effects and the rash resolved in an average of 5.6 weeks. It is important for physicians to be aware of this self-limited reaction so they can reassure and appropriately counsel patients that it is safe to receive subsequent vaccine doses despite the cutaneous eruption. Additionally, differences in incidence of this reaction after Pfizer and Moderna vaccination may suggest a differing host immune response incited by these vaccines which warrants further investigation. |
| first_indexed | 2024-04-12T17:56:45Z |
| format | Article |
| id | doaj.art-90796fa6f6664835b4667f950093d1c6 |
| institution | Directory Open Access Journal |
| issn | 2666-3287 |
| language | English |
| last_indexed | 2024-04-12T17:56:45Z |
| publishDate | 2022-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JAAD International |
| spelling | doaj.art-90796fa6f6664835b4667f950093d1c62022-12-22T03:22:19ZengElsevierJAAD International2666-32872022-06-017164168Pityriasis rosea–like rash after messenger RNA COVID-19 vaccination: A case report and review of the literatureCapsule SummaryJordan E. Buckley, MD0Laura N. Landis, BA1Ronald P. Rapini, MD2Department of Dermatology, The University of Texas Health Science Center, Houston, Texas; Correspondence to: Jordan E. Buckley, MD, Department of Dermatology, The University of Texas Health Science Center, 6655 Travis Street, Suite 980, Houston, TX 77030.McGovern Medical School, The University of Texas Health Science Center, Houston, TexasDepartment of Dermatology, The University of Texas Health Science Center, Houston, TexasA spectrum of cutaneous reactions to SARs-CoV-2 (COVID-19) vaccines have been reported in the literature. We present a case of a pityriasis rosea-like rash occurring after Pfizer COVID-19 vaccination and review cases of pityriasis rosea (PR)/PR-like eruption (PR-LE) after mRNA COVID-19 vaccine published in the medical literature. Of the 30 cases found, none experienced severe adverse effects and the rash resolved in an average of 5.6 weeks. It is important for physicians to be aware of this self-limited reaction so they can reassure and appropriately counsel patients that it is safe to receive subsequent vaccine doses despite the cutaneous eruption. Additionally, differences in incidence of this reaction after Pfizer and Moderna vaccination may suggest a differing host immune response incited by these vaccines which warrants further investigation.http://www.sciencedirect.com/science/article/pii/S2666328722000141coronavirusCOVID-19dermatologyModernamRNA vaccinePfizer |
| spellingShingle | Jordan E. Buckley, MD Laura N. Landis, BA Ronald P. Rapini, MD Pityriasis rosea–like rash after messenger RNA COVID-19 vaccination: A case report and review of the literatureCapsule Summary JAAD International coronavirus COVID-19 dermatology Moderna mRNA vaccine Pfizer |
| title | Pityriasis rosea–like rash after messenger RNA COVID-19 vaccination: A case report and review of the literatureCapsule Summary |
| title_full | Pityriasis rosea–like rash after messenger RNA COVID-19 vaccination: A case report and review of the literatureCapsule Summary |
| title_fullStr | Pityriasis rosea–like rash after messenger RNA COVID-19 vaccination: A case report and review of the literatureCapsule Summary |
| title_full_unstemmed | Pityriasis rosea–like rash after messenger RNA COVID-19 vaccination: A case report and review of the literatureCapsule Summary |
| title_short | Pityriasis rosea–like rash after messenger RNA COVID-19 vaccination: A case report and review of the literatureCapsule Summary |
| title_sort | pityriasis rosea like rash after messenger rna covid 19 vaccination a case report and review of the literaturecapsule summary |
| topic | coronavirus COVID-19 dermatology Moderna mRNA vaccine Pfizer |
| url | http://www.sciencedirect.com/science/article/pii/S2666328722000141 |
| work_keys_str_mv | AT jordanebuckleymd pityriasisrosealikerashaftermessengerrnacovid19vaccinationacasereportandreviewoftheliteraturecapsulesummary AT lauranlandisba pityriasisrosealikerashaftermessengerrnacovid19vaccinationacasereportandreviewoftheliteraturecapsulesummary AT ronaldprapinimd pityriasisrosealikerashaftermessengerrnacovid19vaccinationacasereportandreviewoftheliteraturecapsulesummary |